Cardiol Therapeutics (TSE:CRDL) Stock Price Down 14.6% – Here’s What Happened

Cardiol Therapeutics Inc. (TSE:CRDL)’s share price traded down 14.6% on Tuesday . The company traded as low as C$1.24 and last traded at C$1.29. 551,069 shares traded hands during trading, an increase of 405% from the average session volume of 109,045 shares. The stock had previously closed at C$1.51.

Cardiol Therapeutics Trading Down 14.6%

The business’s 50-day moving average is C$1.50 and its two-hundred day moving average is C$1.64. The company has a current ratio of 2.49, a quick ratio of 6.84 and a debt-to-equity ratio of 1.59. The stock has a market capitalization of C$129.00 million, a PE ratio of -3.15 and a beta of 1.31.

Cardiol Therapeutics (TSE:CRDL) last announced its earnings results on Thursday, November 13th. The company reported C($0.12) EPS for the quarter. On average, analysts predict that Cardiol Therapeutics Inc. will post -0.49 earnings per share for the current year.

Cardiol Therapeutics Company Profile

Cardiol Therapeutics Inc (NASDAQ: CRDL) (TSX: CRDL) is a clinical-stage life sciences company focused on the research and clinical development of anti-inflammatory and anti-fibrotic therapies for the treatment of heart disease. The Company’s lead drug candidate, CardiolRxTM (cannabidiol) oral solution, is pharmaceutically manufactured and in clinical development for use in the treatment of heart disease.